FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting

FSdC spheroids preserved disc height 12.4% better than controls in a 12-week rabbit study.

What the company is saying

FibroBiologics, Inc. is highlighting preclinical results for its fibroblast spheroid-derived chondrocyte (FSdC) spheroids in a rabbit model of degenerative disc disease, presented at the NASS 2026 Annual Meeting. The company frames FSdC spheroids as a potential solution to the cellular and matrix loss underlying disc degeneration, emphasizing statistically significant improvements over both controls and other fibroblast-based approaches. The announcement details that FSdC spheroids achieved an 80.7% normalized disc height index (%DHI) at 12 weeks, compared to 71.8% in controls, with p<0.05 significance. Chief Scientific Officer Hamid Khoja, Ph.D., underscores the platform's design to address disc biology directly, while presenter Nikolay Bazhanov, M.D., Ph.D., stresses the potential for FSdC spheroids to restore lost disc cells. The tone is confident and data-driven, focusing on comparative efficacy and the scientific rationale for the approach. The company does not mention financials, regulatory milestones, or clinical trial timelines, keeping the narrative strictly within the preclinical domain.

What the data suggests

The disclosed data show that FSdC spheroids led to a normalized disc height index (%DHI) of 80.7% at 12 weeks, outperforming the control group's 71.8% (p<0.05). All three fibroblast-based treatments—2D fibroblasts, 3D spheroids, and FSdC spheroids—produced statistically significant improvements over controls, but FSdC spheroids maintained the highest %DHI throughout the study. Chondrogenic differentiation of FSdC spheroids was confirmed by Alcian blue staining and upregulation of cartilage genes (TGFβ1, COMP, SOX9, ACAN). The study used a single injection per animal and monitored outcomes with X-ray, MRI, and tissue analysis over 12 weeks. No financial, commercial, or clinical development data are provided. The evidence is robust for preclinical efficacy in this animal model, but there is no information on translation to humans or regulatory progress.

Analysis

The announcement presents statistically significant preclinical results in a rabbit model, with clear numerical data supporting the efficacy of FSdC spheroids in preserving disc height over 12 weeks. The language is generally proportionate to the evidence, focusing on realised experimental outcomes rather than speculative claims. Forward-looking statements are limited to platform design intent and potential future application, without overpromising clinical or commercial impact. No capital outlay or financial projections are discussed, and there is no suggestion of imminent clinical translation or revenue. The gap between narrative and evidence is minimal, as the claims are well-supported by disclosed data. However, as this is a preclinical update, the path to clinical or commercial benefit remains long-term and uncertain, which tempers the investment signal.

Risk flags

• ●The results are limited to a single 12-week preclinical rabbit model, which may not predict efficacy or safety in humans. Translation from animal models to human clinical outcomes is a major risk in biotech development, and many candidates fail at this stage.
• ●No clinical trial plans, regulatory milestones, or timelines are disclosed, leaving uncertainty about the pathway and timing to human studies and eventual commercialization. This lack of forward guidance increases execution risk for investors.
• ●The announcement does not address manufacturing, scalability, or safety data, which are critical for advancing cell-based therapies beyond preclinical research. Without these details, operational risks remain high.

Bottom line

FibroBiologics, Inc. has produced statistically significant preclinical data showing that its FSdC spheroids preserved disc height 12.4% better than controls over 12 weeks in a rabbit model of degenerative disc disease. The scientific evidence is credible within the animal study context, with clear experimental design and validated chondrogenic differentiation. However, the announcement provides no information on clinical trial readiness, regulatory engagement, or commercial plans, and all benefits are confined to preclinical results. Investors should recognize that the path to human trials and commercial value is still undefined and likely long-term. The most important takeaway is that while the preclinical data are promising, there is no immediate catalyst or near-term value realization; future updates should be watched for clinical advancement or partnership announcements.

Announcement summary

(NASDAQ:FBLG) FibroBiologics, Inc. announced that Nikolay Bazhanov, M.D., Ph.D. presented preclinical data on the company's fibroblast spheroid-derived chondrocyte (FSdC) spheroids for degenerative disc disease (DDD) at the North American Spine Society (NASS) 2026 Annual Meeting. The oral presentation, titled 'Efficacy of fibroblast spheroid-derived chondrocyte spheroids in a rabbit model of degenerative disc disease (Abstract #152)', was delivered on October 15, 2026, from 3:15 p.m. to 3:20 p.m. CT in the Stars at Night Ballroom B2/B3. The preclinical study evaluated three approaches using allogeneic human dermal fibroblasts: conventionally cultured (2D) fibroblasts, three-dimensional (3D) fibroblast spheroids, and fibroblast spheroid-derived chondrocytes (FSdC), with each cell preparation administered as a single injection in a rabbit model of intervertebral disc degeneration. Treatment outcomes were monitored over 12 weeks using periodic X-ray imaging, MRI, and tissue analysis to assess changes in disc structure and degeneration. Chondrogenic differentiation of the FSdC spheroids was confirmed by positive Alcian blue staining and upregulation of cartilage-associated genes TGFβ1, COMP, SOX9, and ACAN. All three fibroblast-treated groups showed higher disc heights than vehicle controls, as measured by normalized percent disc height index (%DHI). In mixed-model analysis, improvements were statistically significant for 2D fibroblasts (p<0.05), fibroblast spheroids (p<0.05), and FSdC spheroids (p<0.01). Throughout the 12-week study, the FSdC spheroid group maintained significantly higher %DHI values than the other treatment groups. At 12 weeks, %DHI was 80.7% in the FSdC spheroid group versus 71.8% in controls (p<0.05). The treatment effects were consistent across the lumbar levels studied. Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, stated that the fibroblast spheroid platform is designed to address the biology of degenerative disc disease by targeting the loss of cells and extracellular matrix. Nikolay Bazhanov, M.D., Ph.D., emphasized that FSdC spheroids are designed to potentially restore lost disc cells by delivering allogeneic cartilage-forming cells directly into the damaged disc, and that FSdCs preserved disc height better than any other approach tested, with this advantage maintained for the full 12 weeks.

Disagree with this article?